BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis

Summary

The primary objective of the study is to investigate whether treatment with BG00012 (dimethyl fumarate) compared with placebo slows the accumulation of disability not related to relapses in participants with secondary progressive multiple sclerosis (SPMS). The secondary objective of the study is to assess the effect of BG00012 compared with placebo on patient-reported outcomes, brain atrophy, and cognitive function.

Timeline

Start

2015-05

Primary completion

2016-01

Completion

2016-01

Drugs

Indications